Healthy Aging
Conditions
Brief summary
The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals. The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.
Detailed description
This study is designed to mitigate the effects of glucose with intermittent oral Canagliflozin for healthy, non-diabetic volunteers of any sex who enroll in the study. Participants will provide informed consent via AgelessRx electronic medical record. If eligible, prescriptions will be provided online through the AgelessRx website (www.agelessrx.com). Participants will be randomized into two arms: Arm A will take 100 mg of canagliflozin each day for a total of 7 doses, while Arm B will take 150 mg of canagliflozin every other day for a total of 4 doses. Participants in Arm B will also be provided a pill cutter to use throughout the trial on the 300mg tablet. All participants will begin the trial on the day that they apply a continuous glucose monitor (considered Day 0) and will be asked to take daily blood pressure reading. After one week of baseline readings, both arms will start their canagliflozin dosing protocols. Participants will be asked to complete 7 total surveys to outline side effects and tolerability, one each day starting after their canagliflozin consumption. Participants will be asked to complete a dietary intake journal through Day 0 -Day 14. Lifesum (https://lifesum.com/) should be used to track Carbohydrate/Protein/Fat consumption. Participants will share their dietary intake journal twice over their participation (Day 7 & Day 14).
Interventions
DRUGInvokana Pill
100 mg and 150 mg doses, taken every day and every-other day, respectively.
Sponsors
AgelessRx
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18-85 2. Any sex 3. Any ethnicity 4. Interest in taking Canagliflozin 5. Approved by the AgelessRx Medical team to take Canagliflozin 6. Willing and technically able to use and operate a continuous glucose monitor 7. Own a CGM-compatible phone 8. Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable 9. Adequate cognitive function to be able to give informed consent
Exclusion criteria
1. Diabetes of any type 2. Taking metformin or any other glucose-lowering medication 3. Other diabetes medication 4. Active malignancy of any kind 5. Clinically relevant renal or kidney disease or dysfunction 6. History of eating disorder 7. Any diuretic 8. Taking any medication, or having any medical condition, that might interfere with the action of canagliflozin or the CGM sensor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in blood glucose values after taking Canagliflozin | 2- weeks | The primary endpoint, average glucose, will be assessed by examining blood glucose (mg/dL) area under curve as measured by CGM. Glucose data on days without Canagliflozin treatment will serve as a control. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related side effects through collected survey responses | 2-weeks | The secondary endpoints of safety and tolerability and urinary glucose excretion will also be assessed. Safety and tolerability will be measured by adverse event reporting, blood pressure monitoring, and by comparing treatment tolerability survey results with control tolerability results through subjective surveys. Urinary glucose excretion will be measured by at-home glucose testing strips. |
Countries
United States
Outcome results
None listed